Home

search

Subjectguide
Journals
Books / Serials / Multimedia
Services
Services

Login for Subscribers
Logout

Sitemap
Help
Contacts


Logo






Vol. 28, No. 4, 2008   

Free Abstract     Article (Fulltext)     Article (PDF 477 KB)     

Original Report: Laboratory Investigation

PPAR-Alpha Agonist Fenofibrate Induces Renal CYP Enzymes and Reduces Blood Pressure and Glomerular Hypertrophy in Zucker Diabetic Fatty Rats
Xueying Zhao, Ling-Yun Li

Department of Physiology, Morehouse School of Medicine, Atlanta, Ga., USA

Address of Corresponding Author

Am J Nephrol 2008;28:598-606 (DOI: 10.1159/000116885)


 goto top of page Key Words

  • Arachidonic acid
  • Eicosanoid
  • Epoxygenase
  • omega-Hydroxylase
  • Diabetic nephropathy

 goto top of page Abstract

We have previously shown that fenofibrate, a peroxisome proliferator-activated receptor-alpha activator, increases renal cytochrome P450 (CYP)-derived eicosanoids and improves endothelial function in pre-diabetic obese rats. The present study was designed to explore the efficacy of fenofibrate on blood pressure and renal injury in the advanced stage of type-2 diabetes. 26-week-old male Zucker diabetic fatty rats (ZDF) were fed fenofibrate (100 mg/kg/day) for 6 weeks. Chronic treatment with fenofibrate normalized systolic blood pressure and reduced glomerular size by 19% in diabetic rats. Western blot and fluorescent immunostaining revealed that the over-expression of collagen type IV and alpha-smooth muscle actin was significantly attenuated in the kidney of fenofibrate-treated ZDF (F-ZDF) rats. In addition, fenofibrate administration dramatically decreased the cyclin D1 protein level in the kidney of diabetic rats. In contrast, renal CYP2C23 and CYP4A proteins were significantly increased in F-ZDF rats. These fenofibrate effects were observed in the absence of significant changes in glucose, insulin or lipid levels. Taken together, our results demonstrate that fenofibrate may lower blood pressure and attenuate glomerular hypertrophy and collagen accumulation through the downregulation of cyclin D1 and upregulation of CYP monooxygenases in the late stage of type-2 diabetes.

Copyright © 2008 S. Karger AG, Basel


 goto top of page Author Contacts

Dr. Xueying Zhao
Department of Physiology, Morehouse School of Medicine
Atlanta, GA 30310 (USA)
Tel. +1 404 752 1902, Fax +1 404 752 1045
E-Mail xzhao@msm.edu


 goto top of page Article Information

Received: November 13, 2007
Accepted: December 22, 2007
Published online: February 14, 2008
Number of Print Pages : 9
Number of Figures : 5, Number of Tables : 1, Number of References : 42

 
Journal Home
Journal Content
Guidelines
Editorial Board
Aims and Scope
Subscriptions
Medline Abstract (ID 18277067)
Download Citation
Cited In



This journal is part of the third subject package of the Karger

Journal Archive Collection

Information on packages (PDF)
Free sample issues


For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service.





copyright  © 2010 S. Karger AG, Basel